eFFECTOR Therapeutics, Inc. has filed a prospectus supplement to update and amend information in its previous prospectus with new data from its Quarterly Report and Current Report. The supplement, filed on May 9, 2024, includes attached Quarterly and Current Reports and is essential for a complete understanding of the updated prospectus. eFFECTOR's common stock and warrants are listed on the Nasdaq under the symbols 'EFTR' and 'EFTRW,' with closing prices of $2.08 and $0.028 respectively as of May 8, 2024. The company, an emerging growth company, has not received approval or disapproval from the SEC or any state securities commission for these securities. The company's financial statements reveal a cash and cash equivalents balance of $15,508,000 as of March 31, 2024, and an accumulated deficit of $188,211,000. eFFECTOR...Show More

eFFECTOR Therapeutics, Inc. has filed a prospectus supplement to update and amend information in its previous prospectus with new data from its Quarterly Report and Current Report. The supplement, filed on May 9, 2024, includes attached Quarterly and Current Reports and is essential for a complete understanding of the updated prospectus. eFFECTOR's common stock and warrants are listed on the Nasdaq under the symbols 'EFTR' and 'EFTRW,' with closing prices of $2.08 and $0.028 respectively as of May 8, 2024. The company, an emerging growth company, has not received approval or disapproval from the SEC or any state securities commission for these securities. The company's financial statements reveal a cash and cash equivalents balance of $15,508,000 as of March 31, 2024, and an accumulated deficit of $188,211,000. eFFECTOR has experienced net losses and negative cash flows since inception, except for 2021 and 2020 due to a gain in fair value and revenue from a Pfizer agreement. The company's ability to continue as a going concern is dependent on additional capital, which may come from equity offerings, collaborations, licenses, or other arrangements.